Immunotherapy and chemo before chemoradiation for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new treatment approach for head and neck cancer that can't be removed with surgery. You would get a combination of an immunotherapy drug (which helps your immune system fight cancer) and chemotherapy first, followed by the standard chemoradiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer (in the voice box, throat behind the voice box, or tonsil area) that is HPV-negative.
- Your cancer is advanced (stage III or IVB) and cannot be removed with surgery.
- You are in fairly good health (able to do daily activities) and your organ function is strong enough for treatment.
- You have not had radiation, chemotherapy, or immunotherapy for this cancer before.
- You do not have an active autoimmune disease or serious heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new HPV-unrelated Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.